Oncostatin-M Differentially Regulates Mesenchymal and Proneural Signature Genes in Gliomas via STAT3 Signaling

Neoplasia (United States)

Volumn 17, Issue 2, 2015, Pages 225-237

  Natesh, Kumar ^a   Bhosale, Dipali ^b   Desai, Aarti ^b   Chandrika, Goparaju ^a   Pujari, Radha ^a,e   Jagtap, Jayashree ^a   Chugh, Ashish ^c   Ranade, Deepak ^d   Shastry, Padma ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b PERSISTENT SYSTEMS LTD   (India)

^c Inamdar Multispeciality Hospital   (India)

^d HOSPITAL AND RESEARCH CENTRE   (India)

^e UNIVERSITY OF PUNE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BCAN PROTEIN; CHI3L1 PROTEIN; DLL3 PROTEIN; FIBRONECTIN; GELATINASE B; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; ONCOSTATIN M; ONCOSTATIN M RECEPTOR; PEPTIDES AND PROTEINS; STAT3 PROTEIN; UNCLASSIFIED DRUG; VIMENTIN; YKL40 PROTEIN; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA; LIFR PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GENE; UPREGULATION; BRAIN TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; INDIRECT FLUORESCENT ANTIBODY TECHNIQUE; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION; GLIOMA; HUMANS; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA SUBUNIT; MESENCHYMAL STROMAL CELLS; ONCOSTATIN M; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-6; RECEPTORS, ONCOSTATIN M; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84989315068     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.01.001     Document Type: Article

References (43)

1. [1] Wang, Y., Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. 2013.
2. [2] Wang, H., Lathia, J.D., Wu, Q., Wang, J., Li, Z., Heddleston, J.M., Eyler, C.E., Elderbroom, J., Gallagher, J., Schuschu, J., et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27 (2009), 2393–2404.
3. [3] Brennan, C.W., Verhaak, R.G., McKenna, A., Campos, B., Noushmehr, H., Salama, S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., et al. The somatic genomic landscape of glioblastoma. Cell 155 (2013), 462–477.
4. [4] Cavaliere, R., Lopes, M.B., Schiff, D., Low-grade gliomas: an update on pathology and therapy. Lancet Neurol 4 (2005), 760–770.
5. [5] Lin, C.L., Lieu, A.S., Lee, K.S., Yang, Y.H., Kuo, T.H., Hung, M.H., Loh, J.K., Yen, C.P., Chang, C.Z., Howng, S.L., et al. The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surg Neurol 60 (2003), 402–406.
6. [6] Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005), 987–996.
7. [7] Cooper, L.A., Gutman, D.A., Chisolm, C., Appin, C., Kong, J., Rong, Y., Kurc, T., Van Meir, E.G., Saltz, J.H., Moreno, C.S., et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 180 (2012), 2108–2119.
8. [8] Burton, E.C., Lamborn, K.R., Feuerstein, B.G., Prados, M., Scott, J., Forsyth, P., Passe, S., Jenkins, R.B., Aldape, K.D., Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 62 (2002), 6205–6210.
9. [9] Freije, W.A., Castro-Vargas, F.E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L.M., Mischel, P.S., Nelson, S.F., Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64 (2004), 6503–6510.
10. [10] Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de, T.N., Weller, M., Kros, J.M., Hainfellner, J.A., Mason, W., Mariani, L., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005), 997–1003.
11. [11] Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Nigro, J.M., Colman, H., Soroceanu, L., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 (2006), 157–173.
12. [12] Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 (2010), 98–110.
13. [13] Carro, M.S., Lim, W.K., Alvarez, M.J., Bollo, R.J., Zhao, X., Snyder, E.Y., Sulman, E.P., Anne, S.L., Doetsch, F., Colman, H., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463 (2010), 318–325.
14. [14] Chen, S.H., Benveniste, E.N., Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev 15 (2004), 379–391.
15. [15] Wallace, P.M., MacMaster, J.F., Rouleau, K.A., Brown, T.J., Loy, J.K., Donaldson, K.L., Wahl, A.F., Regulation of inflammatory responses by oncostatin M. J Immunol 162 (1999), 5547–5555.
16. [16] Heinrich, P.C., Horn, F., Graeve, L., Dittrich, E., Kerr, I., Muller-Newen, G., Grotzinger, J., Wollmer, A., Interleukin-6 and related cytokines: effect on the acute phase reaction. Z Ernahrungswiss 37:Suppl. 1 (1998), 43–49.
17. [17] Modur, V., Feldhaus, M.J., Weyrich, A.S., Jicha, D.L., Prescott, S.M., Zimmerman, G.A., McIntyre, T.M., Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 100 (1997), 158–168.
18. [18] Beatus, P., Jhaveri, D.J., Walker, T.L., Lucas, P.G., Rietze, R.L., Cooper, H.M., Morikawa, Y., Bartlett, P.F., Oncostatin M regulates neural precursor activity in the adult brain. Dev Neurobiol 71 (2011), 619–633.
19. [19] Chavey, C., Bibeau, F., Gourgou-Bourgade, S., Burlinchon, S., Boissiere, F., Laune, D., Roques, S., Lazennec, G., Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res, 9, 2007, R15.
20. [20] Teschendorff, A.E., Journee, M., Absil, P.A., Sepulchre, R., Caldas, C., Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Comput Biol, 3, 2007, e161.
21. [21] Friedrich, M., Hoss, N., Stogbauer, F., Senner, V., Paulus, W., Ringelstein, E.B., Halfter, H., Complete inhibition of in vivo glioma growth by oncostatin M. J Neurochem 76 (2001), 1589–1592.
22. [22] Halfter, H., Stogbauer, F., Friedrich, M., Serve, S., Serve, H., Ringelstein, E.B., Oncostatin M-mediated growth inhibition of human glioblastoma cells does not depend on stat3 or on mitogen-activated protein kinase activation. J Neurochem 75 (2000), 973–981.
23. [23] Krona, A., Jarnum, S., Salford, L.G., Widegren, B., Aman, P., Oncostatin M signaling in human glioma cell lines. Oncol Rep 13 (2005), 807–811.
24. [24] Kalluri, R., EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119 (2009), 1417–1419.
25. [25] Thiery, J.P., Epithelial-mesenchymal transitions in cancer onset and progression. Bull Acad Natl Med, 2009, 1969–1978.
26. [26] Gregory, P.A., Bracken, C.P., Bert, A.G., Goodall, G.J., MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7 (2008), 3112–3118.
27. [27] Park, S.M., Gaur, A.B., Lengyel, E., Peter, M.E., The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22 (2008), 894–907.
28. [28] Bhat, K.P., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J.D., Goodman, L.D., et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24 (2013), 331–346.
29. [29] Catlett-Falcone, R., Landowski, T.H., Oshiro, M.M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J.L., Nunez, G., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999), 105–115.
30. [30] Puthier, D., Bataille, R., Amiot, M., IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29 (1999), 3945–3950.
31. [31] Zetter, B.R., The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer 8 (2008), 647–654.
32. [32] Lakka, S.S., Gondi, C.S., Yanamandra, N., Olivero, W.C., Dinh, D.H., Gujrati, M., Rao, J.S., Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23 (2004), 4681–4689.
33. [33] Atkinson, G.P., Nozell, S.E., Benveniste, E.T., NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 10 (2010), 575–586.
34. [34] Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
35. [35] Zarkoob, H., Taube, J.H., Singh, S.K., Mani, S.A., Kohandel, M., Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein. PLoS One, 8, 2013, e64169.
36. [36] Johansen, J.S., Jensen, B.V., Roslind, A., Price, P.A., Is YKL-40 a new therapeutic target in cancer?. Expert Opin Ther Targets 11 (2007), 219–234.
37. [37] Brantley, E.C., Nabors, L.B., Gillespie, G.Y., Choi, Y.H., Palmer, C.A., Harrison, K., Roarty, K., Benveniste, E.N., Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 14 (2008), 4694–4704.
38. [38] Lo, H.W., Cao, X., Zhu, H., Ali-Osman, F., Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 14 (2008), 6042–6054.
39. [39] Repovic, P., Fears, C.Y., Gladson, C.L., Benveniste, E.N., Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene 22 (2003), 8117–8124.
40. [40] Queen, M.M., Ryan, R.E., Holzer, R.G., Keller-Peck, C.R., Jorcyk, C.L., Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res 65 (2005), 8896–8904.
41. [41] Taniwaki, M., Daigo, Y., Ishikawa, N., Takano, A., Tsunoda, T., Yasui, W., Inai, K., Kohno, N., Nakamura, Y., Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 29 (2006), 567–575.
42. [42] Halliday, J., Helmy, K., Pattwell, S.S., Pitter, K.L., LaPlant, Q., Ozawa, T., Holland, E.C., In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proc Natl Acad Sci U S A 111 (2014), 5248–5253.
43. [43] Colman, H., Zhang, L., Sulman, E.P., McDonald, J.M., Shooshtari, N.L., Rivera, A., Popoff, S., Nutt, C.L., Louis, D.N., Cairncross, J.G., et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol 12 (2010), 49–57.